Index Entries

Mareev V. Yu, Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.Т., Akopyan Z.A., Seredenina E. M., Potapenko A. V., Agapov M.A., Asratyan D.A., Dyachuk L.I., Samokhodskaya L. M., Mershina Е. А., Sinitsyn V. E., Pakhomov P. V., Bulanova M.M., Fuks A.A., Mareev Yu.V., Begrambekova Yu. L., and Kamalov A.A.
May 11, 2020
Kardiologiia
Lomonosov Moscow State University (Russia)

Introduction: The aim of this study was to assess the efficacy and safety of a combination of bromhexine at a dose of 8 mg 4 times a day and spironolactone 50 mg per day in patients with mild and moderate COVID 19…

Results: … Analysis for the group as a whole revealed a statistically significant reduction in hospitalization time from 10.4 to 9.0 days (by 1.5 days, p=0.033) and fever time from 6.5 to 3.9 days (by 2.5 days, p<0.001)… Virus elimination by the 10th day was recorded in all patients in the bromhexine/spironolactone group; the control group viremia continued in 23.3% (p=0.077). The number of patients who had a positive PCR to the SARS-CoV-2 virus on the 10th day of hospitalization or longer (≥10 days) hospitalization in the control group was 20/21 (95.2%), and in the group with bromhexine/spironolactone –14/24 (58.3%), p=0.012…

Conclusion: The combination of bromhexine with spironolactone appeared effective in treating a new coronavirus infection by achieving a faster normalization of the clinical condition, lowering the temperature one and a half times faster, and reducing explanatory combine endpoint the viral load or long duration of hospitalization (≥10 days).”

document
bromhexine,COVID-19,medical treatments,pharmaceuticals